Taysha Gene Therapies, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Taysha Gene Therapies, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 1, 2026, to elect directors, ratify auditor selection, and vote on executive compensation.
NASDAQ
Taysha Gene Therapies files an amendment to its proxy statement solely to include Inline eXtensible Business Reporting Language (XBRL) data tagging, which was initially omitted.
NASDAQ
DEFA14A: Taysha Gene Therapies to Hold 2025 Annual Meeting, Seeks Stockholder Approval for Key Proposals
Taysha Gene Therapies is holding its 2025 Annual Meeting on June 2, 2025, seeking stockholder votes on director elections, auditor ratification, and an increase in authorized common stock.
NASDAQ
Taysha Gene Therapies is holding its annual stockholder meeting on June 2, 2025, to vote on director elections, auditor ratification, and an increase in authorized common stock.
NASDAQ
DEFA14A: Taysha Gene Therapies Sets Date for 2024 Annual Meeting, Outlines Proposals for Stockholder Vote
Taysha Gene Therapies announces its 2024 Annual Meeting of Stockholders, urging shareholders to vote on key proposals including the election of directors and ratification of the company's independent auditor.
NASDAQ
DEF 14A: Taysha Gene Therapies Sets Date for 2024 Annual Stockholders Meeting, Outlines Key Proposals
Taysha Gene Therapies announces its Annual Meeting of Stockholders to be held virtually on May 29, 2024, featuring proposals for director elections and ratification of the company's independent accounting firm.